CYP2D6 News and Research

RSS

New personalized therapy boosts tamoxifen effectiveness in breast cancer patients

Breast cancer is the most common cancer among women worldwide (WHO, 2023). The Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP) has now developed a new therapy in a clinical study that tailors hormone treatment for breast cancer to the individual patient.

16 Oct 2025

Common painkiller and antidepressant combo may increase seizure risk in older adults

When older adults living in nursing homes are prescribed the pain medicine tramadol alongside certain antidepressants, their risk of seizures may go up, according to a study published October 8, 2025, in Neurology, the medical journal of the American Academy of Neurology.

8 Oct 2025

Khat use linked to autoimmune hepatitis in young men

Khat (Catha edulis), a plant chewed for its stimulant effects by millions in East Africa and the Arabian Peninsula, is increasingly recognized for its hepatotoxic potential.

30 Sep 2025

Pharmacogenomic testing could help reduce adverse drug reactions in the UK

A new study from Queen Mary University of London found that 9% of all reported adverse drug reactions (ADRs) reported to the UK medicines regulator are associated with medications where side effect risk is partly dependent on patient's genes.

27 Mar 2025

Leveraging genetic variations for more effective cancer therapies

By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against cancer cells in specific patient groups.

14 Nov 2024

Pharmacogenomics holds promise for personalized dementia therapies

Pharmacogenomics-based studies in the research for personalized therapeutics for dementia

8 Nov 2023

AMP releases consensus recommendations for CYP3A4 and CYP3A5 genotyping assays

The Association for Molecular Pathology (AMP), the premier global molecular diagnostic professional society, today published consensus recommendations to aid in the design and validation of clinical CYP3A4 and CYP3A5 genotyping assays, promote standardization of testing across different laboratories, and improve patient care.

10 Jul 2023

Identifying and managing drug-drug interactions key to the safe use of nirmatrelvir–ritonavir in COVID-19 treatment

Researchers compiled evidence-based recommendations in consultation with European and North American clinicians and pharmacologists for recognizing and managing drug-drug interactions with nirmatrelvir–ritonavir.

3 Mar 2022

AMP’s new consensus can promote standardization of PGx gene/allele testing, improve patient care

The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today published consensus recommendations to aid in the design and validation of clinical CYP2D6 assays, promote standardization of testing across different laboratories and improve patient care

11 Jun 2021

Interaction between antidepressants and opioid pain medication contributes to lesser pain relief

Common antidepressants interact with the opioid pain medication tramadol to make it less effective for pain relief, according to a study from University Hospitals.

26 Jun 2019

Scientists discover new drug target for chemically induced Parkinson's disease

More than three decades ago, scientists discovered that a chemical found in a synthetic opioid, MPTP, induced the onset of a form of Parkinson's disease.

23 Jun 2019

Initial gene analysis could result in more effective antipsychotic treatment

An initial gene analysis may yield better outcomes when patients are treated with the antipsychotic drugs risperidone and aripiprazole.

16 Apr 2019

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.

26 Oct 2018

Study highlights need for population-specific precision medicine programs in Latin America

Drug safety and effectiveness vary greatly among populations worldwide. Genetics is one of the factors that contribute to variability in drug response.

3 Oct 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

New clinical practice guideline for using CYP2D6 genotype to guide tamoxifen therapy

An international group of clinicians and scientists representing the Clinical Pharmacogenetics Implementation Consortium published the first-ever clinical practice guideline for using CYP2D6 genotype to guide tamoxifen therapy in Clinical Pharmacology and Therapeutics.

1 Feb 2018

CYP2D6 News and Research

New personalized therapy boosts tamoxifen effectiveness in breast cancer patients

Common painkiller and antidepressant combo may increase seizure risk in older adults

Khat use linked to autoimmune hepatitis in young men

Pharmacogenomic testing could help reduce adverse drug reactions in the UK

Leveraging genetic variations for more effective cancer therapies

Pharmacogenomics holds promise for personalized dementia therapies

AMP releases consensus recommendations for CYP3A4 and CYP3A5 genotyping assays

Identifying and managing drug-drug interactions key to the safe use of nirmatrelvir–ritonavir in COVID-19 treatment

AMP’s new consensus can promote standardization of PGx gene/allele testing, improve patient care

Interaction between antidepressants and opioid pain medication contributes to lesser pain relief

Scientists discover new drug target for chemically induced Parkinson's disease

Initial gene analysis could result in more effective antipsychotic treatment

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Study highlights need for population-specific precision medicine programs in Latin America

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

New clinical practice guideline for using CYP2D6 genotype to guide tamoxifen therapy

New drug shows promise to treat women with estrogen positive metastatic breast cancer

Licorice could pose health risk by interacting with medications

Mayo Clinic highlights potential merits of individualizing treatment for patients taking antidepressants

Study reveals why anti-hormone therapy tamoxifen works better in some women than others

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News